Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody

Endocrinology (United States)

Volumn 155, Issue 12, 2014, Pages 4785-4797

  Li, Xiaodong ^a   Niu, Qing Tian ^a   Warmington, Kelly S ^a   Asuncion, Franklin J ^a   Dwyer, Denise ^a   Grisanti, Mario ^a   Han, Chun Ya ^a   Stolina, Marina ^a   Eschenberg, Michael J ^a   Kostenuik, Paul J ^a   Simonet, William S ^a   Ominsky, Michael S ^a   Ke, Hua Zhu ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; SOST PROTEIN, RAT;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; BONE DENSITY; BONE REMODELING; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETIC MARKER; MICRO-COMPUTED TOMOGRAPHY; OSTEOPOROSIS; OVARIECTOMY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DRUG EVALUATION, PRECLINICAL; FEMALE; GENETIC MARKERS; OSTEOPOROSIS; OVARIECTOMY; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; X-RAY MICROTOMOGRAPHY;

EID: 84914124216     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1905     Document Type: Article

References (32)

1. Beighton P, Durr L, Hamersma H. The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med. 1976;84:393-397.
2. Beighton P, Cremin BJ, Hamersma H. The radiology of sclerosteosis. Br J Radiol. 1976;49:934-939.
3. Beighton P. Sclerosteosis. J Med Genet. 1988;25:200-203.
4. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63:192-197.
5. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589.
6. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-543.
7. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-6276.
8. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869.
9. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-588.
10. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25:2371-2380.
11. Tian X, Jee WS, Li X, Paszty C, Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011;48:197-201.
12. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009;24:1662-1671.
13. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26:1012-1021.
14. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dick-kopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33:747-783.
15. Ominsky MS, Vlasserros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948-959.
16. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
17. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2013;54:168-178.
18. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-420.
19. National Research Council (US) Committee for the Update of the Guide of the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press (US); 2011. http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-animals.pdf.
20. Kostenuik PJ, Capparelli C, Morony S, et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001;142:4295-4304.
21. Ominsky MS, Li X, Asuncion FJ, et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res. 2008;23:672-682.
22. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
23. Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res. 1990;8:612-617.
24. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010;47:529-533.
25. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152:3312-3322.
26. Frost HM. Bone "mass" and the "mechanostat": a proposal. Anat Rec. 1987;219:1-9.
27. Li XJ, Jee WS. Adaptation of diaphyseal structure to aging and decreased mechanical loading in the adult rat: a densitometric and histomorphometric study. Anat Rec. 1991;229:291-297.
28. Pead MJ, Skerry TM, Lanyon LE. Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading. J Bone Miner Res. 1988;3:647-656.
29. van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26:2804-2811.
30. Wronski TJ, Yen CF, Qi H, Dann LM. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 1993;132:823-831.
31. Liu M, Kurimoto P, Niu Q, et al. Decreased osteoclastogenesis in bone marrow cells derived from ovariectomized rats treated with sclerostin antibody (Abstract). J Bone Miner Res. 2012;27:S207.
32. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-764.